Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Scrip Asia 100 - Influential Asia-Pacific pharma and biotech players

This article was originally published in Scrip

Executive Summary

Company Country - HQ Principal officer - Role Focus/ area of specialty News flow Financial performance (FY 2009) ADImmune Taiwan - Taipei Ignatius Wei - President vaccine development and commer- cialisation n/a private company AnGes MG Japan - Osaka Ei Yamada - President and CEO drug development AnGes MG is granted a patent in Japan for a new decoy oligonucleotide (2009) total revenue: Yen585 million aRigen Japan - Tokyo Gensuke Tokoro - President and CEO drug discovery and development aRigen and CJ CheilJedang sign an agreement to jointly develop ARH-1029 for the treatment of peptic ulcer disease (2010) private company Astellas Japan - Tokyo Masafumi Nogimori - President and CEO drug development and commer- cialisation Astellas completes $ 4 billion acquisition of OSI Pharmaceuticals (2010) net sales: Yen974.88 billion Crystal Genomics South Korea - Seoul Dr Cho Joong Myung* - President and CEO drug discovery and development CrystalGenomics to merge with BexPharm, a South Korean speciality pharmaceutical company (2010) private company Daiichi Sankyo Japan - Tokyo Takashi Shoda - President and CEO drug development and commer- cialisation Daiichi Sankyo launches Rezaltas combination tablets for the treatment of hypertension in Japan (2010) net sales: Yen952.1 billion Eisai Japan - Tokyo Haruo Naito - President and CEO drug development and commer- cialisation Eisai establishes new sales subsidiary in Canada (2010) net sales: Yen803 billion Fujifilm Japan - Tokyo Shigetaka Komori - President and CEO divisions for medical imaging and diagnostics Fujifilm’s subsidiaries, Perseus Proteomics and Fujifilm RI Pharma, present the development of a new radiolabelled anticancer antibody to a meeting of the Society of Nuclear Medicine (2010) revenue: Yen2,434 billion Histostem South Korea - Seoul Dr Hoon Han - President biotechnology n/a private company Hutchison Medipharma ** China - Shanghai Dr Samantha Du - CEO drug discovery and development signs agreement with Ortho-McNeil-Janssen Pharmaceuticals to discover and develop therapeutics to treat inflammatory and immune diseases (2008) sales: $111 million (parent company) HUYA Bioscience China - Shanghai and San Diego, US Dr Mireille Gingras - CEO biopharmaceutical development Huya announces a strategic partnership with the School of Chinese Materia Medica of the Beijing University of Chinese Medicine (2010) private company Indofarma Indonesia - Jakarta P Sudibyo - Managing director drug development and commer- cialisation Indofarma and 3M Indonesia sign a partnership to market, distribute and sell 3M’s nitroglycerin transdermal patch system (2010) private company Innova Biotech Thailand - Bangkok n/a - n/a immuno- diagnostics n/a private company Kalbe Farma Indonesia - Jakarta Johannes Setijono - President and director drug development and commer- cialisation n/a sales: Rupiah9,087 billion LG Life Sciences South Korea - Seoul Kim In-Chull* - President and CEO drug development and commer- cialisation LG Life Sciences announces the discovery of new necrosis inhibitors (2009) sales: Won327.3 billion Macrogen South Korea - Seoul Seo Jeongsun - Chairman biotechnology Macrogen research team publishes a genome map of a Korean male in the journal Nature (2009) sales: Won22.46 billion Medigen Biotechnology Taiwan - Taipei Dr Stanley Chang* - Chairman and CEO drug development and diagnostics Medigen receives ASHI laboratory accreditation for HLA typing (2009) n/a Medipost South Korea - Yongin-si Jin Chang-Hyun - CEO biotechnology n/a n/a MerLion Pharma Singapore - Singapore Dr Tony Buss - President and CEO contract research and drug development MerLion and Chaperone Technologies collaborate on the development of new antimicrobials (2009) private company MicuRx/ Cumencor Pharma (MicuRx’s Chinese affiliate) China - Shanghai and Hayward, CA, US Dr Yuan Zhengyu - President and CEO drug discovery and development MicuRx and Cumenor Pharmaceuticals partner with Pfizer to discover and develop antibiotics for drug-resistant TB in China (2010); MicuRx raises $10 million in a series A financing round (2007) private company Moleac Singapore - Singapore David Picard - CEO drug development and commer- cialisation opens office in Paris, France (2009); launches NeuroAiD in Iran, Jordan, Pakistan and Thailand (2009) private company RNL Bio South Korea - Seoul Dr Ra Jeong-Chan - President biotechnology RNL Bio and Start Licensing settle patent disputes and conclude a licence agreement on animal cloning (2010) private company S*BIO Singapore - Singapore Dr Jan-Anders Karlsson*** - CEO drug development S*Bio presents positive safety and tolerability results for its novel oral JAK2 inhibitor SB1518 from a Phase I/II study for the treatment of myelofibrosis (2010) private company Shenzhen SiBiono GeneTech China - Shenzhen Dr Peng Zhaohin - Chairman and CEO gene therapy n/a n/a Shionogi Japan - Osaka Dr Isao Teshirogi - President drug development and commer- cialisation Shionogi announces the establishment of a new Japanese research subsidiary, Shionogi Techno Advance Research (2010) net sales: Yen227.5 billion Sinovac Biotech China - Beijing Dr Yin Weidong* - President and CEO vaccine development and commer- cialisation Sinovac completes $17.6 million buildings and land acquisition to expand vaccine production capacity (2010) sales: $84.20 million TaiGen Biotech Taiwan - Taipei Dr Hsu Ming-Chu* - Chairman, president and CEO drug discovery TaiGen raises $37 million in a series C financing round (2009) private company TaiMed Biologics Taiwan - Taipei James Chang - CEO drug development n/a private company Taiwan Biotech Taiwan - Taoyuan City n/a - n/a drug development and commer- cialisation n/a private company Takara Bio Japan - Shiga Koichi Nakao - President and CEO biotechnology Takara Bio executes a collaborative research agreement with the University of Pennsylvania to support an HIV gene therapy clinical trial in the US (2010) net sales: Yen18,913 million Takeda Japan - Osaka Yasuchika Hasegawa - President drug development and commercialisation Takeda plans to establish a new commercial subsidiary in South Korea (2010) sales: Yen1,466 billion UMN Pharma Japan - Akita City Dr Shu-Ichi Kanazashi - President and CEO drug development and commer- cialisation UMN Pharma and API Co announce formulation process collaboration for influenza vaccine candidate UMN-0501 (2010) private company United Laboratories (Unilab) Philippines - Mandaluyong City Jocelyn Campos-Hess - Chairperson drug development and commer- cialisation n/a private company Viromed South Korea - Seoul Dr Kim Sunyoung and Kim Yongsoo - Co-CEOs drug development Viromed completes merger with Helixir Co, a developer of phytotherapeutics (2009) revenues: $7.66 million

*Scrip Asia 100 ’Shining Star’; **Hutchinson China MediTech, part of Chi-Med; ***interviewed in Scrip Asia 100

Source: Scrip analysis

You may also be interested in...



2011 Scrip Asia 100 - Abbott bullish about India but must work hard to retain crown

One year after acquiring Piramal's Domestic Formulations business in a deal that made it India's largest pharmaceutical player, Abbott remains confident about its growth prospects in India, where it hopes to be generating $2.5 billion in sales by 2020. But facing fierce competition from domestic firms, Abbott isn't about to get complacent, Michael Warmuth, senior VP of the company's Established Products Division, tells Pete Chan. This article is part of the 2011 Scrip Asia 100.

2011 Scrip Asia 100 - Asia life science-focused VC firms

Asia life science-focused VC firms*

2011 Scrip 100: Re-engineering Roche

Roche is overhauling its cost structure to produce a leaner organisation better equipped to focus on the business of pharmaceutical innovation. It is also investing heavily in China, turning its Shanghai operations into a centre for everything from commercial manufacturing and research to partnering, licensing and strategic planning. Pascal Soriot, chief operating officer of Roche Pharmaceuticals, speaks to Pete Chan in an exclusive interview.

Topics

Related Companies

UsernamePublicRestriction

Register

SC009320

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel